10-Q/A: SS Innovations Restates Financials for Q3 2024, Citing Material Errors and Internal Control Weaknesses

SS Innovations International restated its Q3 2024 financials due to material errors and weaknesses in internal controls, leading to a re-evaluation of financial reporting effectiveness.

Summary

• SS Innovations International, Inc. has amended its Form 10-Q for the quarter ended September 30, 2024, to restate its previously issued interim unaudited condensed consolidated financial statements.
• The restatement was due to the discovery of material errors in prior filed audited and interim unaudited financial statements.
• The company's management concluded that its disclosure controls and procedures and internal controls over financial reporting were not effective as of September 30, 2024, due to material weaknesses related to accounting errors.
• The company sold 21 systems during the nine months ended September 30, 2024.
• The company incurred a net loss of $17,227,806 for the nine months ended September 30, 2024, compared to a net loss of $8,736,042 for the same period in 2023.
• Revenue for the nine months ended September 30, 2024, was $12,533,335, compared to $4,448,939 for the same period in 2023.
• The company has raised significant funding through convertible promissory notes, including $2,450,000 between February 1 and February 14, 2024, and additional amounts in April and July 2024.
• The company's auditors and the audit committee have been informed of the significant deficiencies and material weaknesses in internal control over financial reporting.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the restatement of financials, material weaknesses in internal controls, and increased net losses, although revenue growth provides a somewhat positive offset.

Positives

• Revenue increased significantly for both the three and nine months ended September 30, 2024, compared to the corresponding periods in 2023.
• The company has successfully raised capital through private offerings and convertible notes.
• The company sold 21 surgical robotic systems during the nine months ended September 30, 2024.
• Gross profit increased to $2,317,407 for the three months ended September 30, 2024, from $298,848 for the three months ended September 30, 2023.

Negatives

• Material weaknesses in internal control over financial reporting were identified.
• The company restated its financial statements due to material errors.
• The company incurred a net loss of $3,245,483 for the three months ended September 30, 2024, and $17,227,806 for the nine months ended September 30, 2024.
• Stock compensation expense significantly increased to $12,003,897 for the nine months ended September 30, 2024, from $32,600 in the same period of 2023.
• The company's management concluded that its disclosure controls and procedures and internal controls over financial reporting were not effective as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• There are no committed sources of funding, and there is no assurance that the company will be able to secure additional funding.
• The company may be forced to curtail operations or consider other strategic alternatives if it cannot obtain financing.
• The company faces a legal proceeding in the Bahamas regarding a disputed shareholding in Otto Pvt Ltd.
• The company's disclosure controls and procedures and internal controls over financial reporting were not effective as of September 30, 2024.

Future Outlook

The company plans to raise additional capital through further private or public offerings to scale up operations and finance research and development.

Management Comments

• Management of the Company is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.
• Our Chief Executive Officer and Chief Financial Officer do not expect that our disclosure controls or internal controls will prevent all errors and all fraud.

Industry Context

The company operates in the surgical robotics industry, which is experiencing increasing recognition of robotically assisted surgeries as an approved treatment modality from an insurance coverage perspective.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Comparable companies in the surgical robotics industry include Intuitive Surgical, Stryker, and Medtronic.
• Without specific benchmarks for revenue growth, profitability, and R&D spending, a thorough assessment is not possible.
• The document mentions cost advantages due to manufacturing operations being based in India, which could be a competitive advantage compared to companies with higher manufacturing costs.

Legal Proceedings

• An ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares (approximately a 9% interest) in Otto.

Related Party Transactions

• The company has raised significant funding through convertible promissory notes from affiliates.
• Receivable from related party amounting to $1,228,225 and $1,567,559 as at September 30, 2024 and December 31, 2023 respectively, majorly consists proceeds of convertible promissory notes raised by the Company from the investors during the respective years, but collected by related entities on its behalf.

Stakeholder Impact

• Shareholders may be concerned about the restatement of financials and material weaknesses in internal controls.
• Employees may be affected by the company's efforts to remediate the identified material weaknesses.
• Customers and suppliers may be affected by the company's ability to continue as a going concern.
• Creditors may be affected by the company's ability to obtain additional financing.

Next Steps

• The company is implementing a new ERP system to integrate all business functions within the accounting and financial department.
• The company is enhancing the review process for significant transactions to ensure proper accounting treatment.
• The company is engaging external experts where necessary to assist in the application of accounting principles to complex transactions.
• The company is addressing and remediating the identified material weaknesses with the support and assistance of the accounting and financial staff employed by its Indian operating subsidiary.

Key Dates

Keywords

restatement, financial statements, internal control, material weaknesses, revenue, net loss, surgical robotic systems, SS Innovations, convertible notes, financing, Form 10-Q, Q3 2024